al., placed pro-proliferative IGF2BPs among differentially expressed genes of the immunotherapy responders versus non-responders, which are downregulated in “on-therapy” samples as well as some of their previously described mRNA targets e.g., MITF, MYC, HOXB9. Future studies will shed light on the mechanisms by which IGF2BPs alter interferon pathways and establish a possible application of IGF2BP inhibitors alongside immunotherapies in human cancers. This evidence concerns the gene HOXB9 and cancer.